| Name |
Recombinant Human BTN2A1/Butyrophilin 2A1 Protein, CF
|
| Supplier |
R&D Systems
|
| Catalog |
9058-BT
|
| Category |
Protein
|
| Prices |
$339.00
|
| Sizes |
50 µg
|
| Species Reactivities |
Human
|
| Nature |
Recombinant
|
| Source |
Human embryonic kidney cell, HEK293-derived Gln29-Ala248, with a C-terminal 6-His tag
|
| Purity |
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
|
| Bioactivity |
Measured by its binding ability in a functional ELISA. When Recombinant Human BTN2A1 is immobilized at 1 µg/mL (100 µL/well), the concentration of Recombinant Human DC‑SIGN/CD209 Fc Chimera (Catalog # 161-DC ) that produces 50% of the optimal binding response is approximately 0.1-0.5 μg/mL.
|
| Endotoxin |
<0.10 EU per 1 μg of the protein by the LAL method.
|
| SwissProt/Accession |
Q7KYR7
|
| Gene |
BTN2A1
|
| Sequence |
No results obtained. Gln29 predicted
|
| Supplier Page |
Shop
|
When Recombinant Human BTN2A1/Butyrophilin 2A1 (Catalog # 9058-BT) is coated at 1 µg/mL, Recombinant Human DC-SIGN/CD209 Fc Chimera (Catalog # 161-DC) binds with a typically ED 50 of 0.1-0.5 μg/mL.